EE05385B1 - LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon - Google Patents

LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon

Info

Publication number
EE05385B1
EE05385B1 EEP200300381A EEP200300381A EE05385B1 EE 05385 B1 EE05385 B1 EE 05385B1 EE P200300381 A EEP200300381 A EE P200300381A EE P200300381 A EEP200300381 A EE P200300381A EE 05385 B1 EE05385 B1 EE 05385B1
Authority
EE
Estonia
Prior art keywords
ákuiáhiváprotease
áamino
useunited
sulphonamides
benzothiazole
Prior art date
Application number
EEP200300381A
Other languages
English (en)
Estonian (et)
Inventor
Dominique�Louis�Nestor�Ghislain�Surleraux
Piet�Tom�Bert�Paul�Wigerinck
Daniel�Getman
Wim�Gaston�Verschueren
Sandrine�Marie�Helene�Vendeville
Marie-Pierre�T.M.M.G�De�Bethune
Jan�Octaaf�Antoon�De�Kerpel
Samuel�Leo�Christiaan�Moors
Herman�Augustinus�De�Kock
Marieke�Christiane�Johanna�Voets
Original Assignee
Tibotec�Pharmaceuticals�Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec�Pharmaceuticals�Ltd. filed Critical Tibotec�Pharmaceuticals�Ltd.
Publication of EE200300381A publication Critical patent/EE200300381A/xx
Publication of EE05385B1 publication Critical patent/EE05385B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200300381A 2001-02-14 2002-02-14 LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon EE05385B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01200529 2001-02-14
US28775801P 2001-05-02 2001-05-02
PCT/EP2002/001788 WO2002083657A2 (en) 2001-02-14 2002-02-14 Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors

Publications (2)

Publication Number Publication Date
EE200300381A EE200300381A (et) 2003-12-15
EE05385B1 true EE05385B1 (et) 2011-02-15

Family

ID=26076833

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300381A EE05385B1 (et) 2001-02-14 2002-02-14 LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon

Country Status (31)

Country Link
US (1) US7659404B2 (no)
EP (1) EP1370543B1 (no)
JP (1) JP4530612B2 (no)
KR (1) KR100870184B1 (no)
CN (2) CN100369904C (no)
AP (1) AP1504A (no)
AT (1) ATE343567T1 (no)
AU (1) AU2002302363B2 (no)
BG (1) BG66301B1 (no)
BR (1) BR0207862A (no)
CA (1) CA2438304C (no)
CY (1) CY1108073T1 (no)
CZ (1) CZ304273B6 (no)
DE (1) DE60215623T2 (no)
DK (1) DK1370543T3 (no)
EA (1) EA006096B1 (no)
EE (1) EE05385B1 (no)
ES (1) ES2275866T3 (no)
HK (1) HK1061233A1 (no)
HR (1) HRP20030735B1 (no)
HU (1) HU229224B1 (no)
IL (2) IL157171A0 (no)
MX (1) MXPA03007236A (no)
NO (1) NO326174B1 (no)
NZ (1) NZ527391A (no)
PL (1) PL213327B1 (no)
PT (1) PT1370543E (no)
SI (1) SI1370543T1 (no)
SK (1) SK287582B6 (no)
WO (1) WO2002083657A2 (no)
ZA (1) ZA200306086B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246859T3 (es) 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
WO2002033638A2 (en) 2000-10-20 2002-04-25 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US7659404B2 (en) 2001-02-14 2010-02-09 Tibotec Pharmaceuticals Ltd. Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
EP1472536A4 (en) 2002-01-07 2007-02-14 Sequoia Pharmaceuticals VERSATILE INHIBITORS
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
EP1520247B1 (en) 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
EP1522039B1 (en) 2002-07-01 2008-06-04 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
OA12893A (en) * 2002-08-02 2006-10-13 Tibotec Pharm Ltd Broadspectrum 2-Amino-Benzothiazole Sulfonamide HIV Protease Inhibitors.
WO2004014371A1 (en) * 2002-08-02 2004-02-19 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors
ATE353323T1 (de) * 2003-09-30 2007-02-15 Tibotec Pharm Ltd Verfahren zur herstellung von benzoxazolsulfonamidverbindungen und zwischenprodukten davon
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
JP5073480B2 (ja) * 2004-05-07 2012-11-14 セコイア、ファーマシューティカルズ、インコーポレイテッド 耐性防止レトロウイルスプロテアーゼ阻害薬
DK1856125T3 (da) 2005-02-25 2009-12-07 Tibotec Pharm Ltd Syntese af proteasehæmmerforstadie
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
JO2841B1 (en) 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
US9024038B2 (en) 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
NZ622769A (en) 2012-04-20 2017-06-30 Gilead Sciences Inc Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
CN104000824B (zh) * 2014-05-28 2016-07-06 中山大学 苯并五元杂环类化合物在制备抗hiv-1病毒药物中的应用
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
WO2024206093A1 (en) * 2023-03-24 2024-10-03 Purdue Research Foundation Hiv-1p rotease inhibitors and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69121436T2 (de) 1990-03-09 1997-01-09 Milliken Res Corp Organische Materialien, die sulfonamidogebundene Poly(oxyalkylen)gruppen tragen und ihre Herstellung
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1995006030A1 (en) 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
PT810209E (pt) 1992-08-25 2002-09-30 Searle & Co Hidroxietilamino-sulfonamidas de alfa- e beta-aminoacidos uteis como inibidores de protease retroviral
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
PL175564B1 (pl) 1993-10-01 1999-01-29 Astra Ab Sposób i urządzenie do formowania leku w proszku oraz lek w proszku
EP1586558A3 (en) 1995-01-20 2005-10-26 G.D. Searle LLC. Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors
US6140505A (en) 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6143788A (en) * 1995-03-10 2000-11-07 G.D. Searle & Co. Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors
AU717598B2 (en) * 1995-03-10 2000-03-30 G.D. Searle & Co. Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6861539B1 (en) * 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
JP2000515488A (ja) * 1995-11-15 2000-11-21 ジー．ディー．サール アンド カンパニー 置換スルホニルアルカノイルアミノヒドロキシエチルアミノスルホンアミド レトロウイルスプロテアーゼ阻害剤
CN1165291C (zh) 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
ES2201485T3 (es) 1997-03-26 2004-03-16 Janssen Pharmaceutica N.V. Palets que tienen un nucleo recubierto con un agente antifungico y un polimero.
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
CN1110492C (zh) * 1997-12-24 2003-06-04 沃泰克斯药物股份有限公司 天冬氨酰蛋白酶抑制剂的前药
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
WO1999065870A2 (en) * 1998-06-19 1999-12-23 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
WO1999067254A2 (en) 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
JP4776775B2 (ja) * 1998-06-23 2011-09-21 アメリカ合衆国 Ｈｉｖ感染哺乳動物を治療するための医薬組成物
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
US7659404B2 (en) 2001-02-14 2010-02-09 Tibotec Pharmaceuticals Ltd. Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors

Also Published As

Publication number Publication date
HRP20030735B1 (en) 2012-02-29
CZ304273B6 (cs) 2014-02-12
IL157171A (en) 2012-10-31
DE60215623D1 (de) 2006-12-07
EP1370543A2 (en) 2003-12-17
SI1370543T1 (sl) 2007-04-30
CZ20032415A3 (cs) 2004-04-14
PL363778A1 (en) 2004-11-29
HK1061233A1 (en) 2004-09-10
SK11022003A3 (sk) 2004-07-07
PT1370543E (pt) 2007-02-28
HRP20030735A2 (en) 2005-08-31
EA006096B1 (ru) 2005-08-25
CN1525962A (zh) 2004-09-01
CN101230067B (zh) 2011-06-15
US7659404B2 (en) 2010-02-09
WO2002083657A3 (en) 2003-02-13
NO20033584D0 (no) 2003-08-13
AP1504A (en) 2005-12-10
AU2002302363B2 (en) 2008-05-01
EP1370543B1 (en) 2006-10-25
EE200300381A (et) 2003-12-15
KR20030077017A (ko) 2003-09-29
CA2438304A1 (en) 2002-10-24
CA2438304C (en) 2011-04-12
DK1370543T3 (da) 2007-02-19
WO2002083657A2 (en) 2002-10-24
SK287582B6 (sk) 2011-03-04
CN101230067A (zh) 2008-07-30
HUP0303257A2 (hu) 2004-01-28
HU229224B1 (en) 2013-09-30
IL157171A0 (en) 2004-02-08
EA200300891A1 (ru) 2004-02-26
MXPA03007236A (es) 2003-12-04
KR100870184B1 (ko) 2008-11-24
BR0207862A (pt) 2004-06-22
ZA200306086B (en) 2005-01-26
NO20033584L (no) 2003-10-14
PL213327B1 (pl) 2013-02-28
US20040116485A1 (en) 2004-06-17
CY1108073T1 (el) 2014-02-12
CN100369904C (zh) 2008-02-20
JP2004518767A (ja) 2004-06-24
JP4530612B2 (ja) 2010-08-25
NZ527391A (en) 2005-04-29
ES2275866T3 (es) 2007-06-16
AP2003002856A0 (en) 2003-09-30
BG66301B1 (bg) 2013-03-29
ATE343567T1 (de) 2006-11-15
DE60215623T2 (de) 2007-08-30
NO326174B1 (no) 2008-10-13
BG108143A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
EE05385B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
NO20033556D0 (no) Farmasöytiske preparater
DK1478339T3 (da) Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
IS7714A (is) Lyfjasamsetningar úr módafíníl
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
NO20033384D0 (no) Farmasöytisk formulering
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
NO20033785L (no) Farmasöytisk formulering
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20041272L (no) Tetracycline derivatives and methods of use thereof
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
NO20044916L (no) Preparater av sulfinylacetamid
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
NO20035627D0 (no) Farmasöytisk formulering
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20035328D0 (no) Nye forbindelser og preparater som katepsinhibitorer
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
EE05384B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensoksasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁkasutamine,ÁfarmatseutilineÁkompositsioonÁjaÁmeetodÁretroviiruseÁreplikatsiooniÁinhibeerimiseks
DK1407780T3 (da) Farmaceutisk stabile hæmostatiske præparater
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
NO20033117D0 (no) Farmasoytiske blandinger som inhiberer vaskulor proliferasjon og metoder for anvendelse derav
NO331227B1 (no) Lineaere basiske forbindelser som har NK-2 antagonistaktivitet, farmasoytiske formuleringer derav og anvendelse av samme for fremstilling av farmasoytiske formuleringer

Legal Events

Date Code Title Description
HE1A Change of address
HE1A Change of address
MM4A Lapsed by not paying the annual fees

Effective date: 20160214